An update on obsessive-compulsive disorder.

It is now recognized that obsessive-compulsive disorder (OCD) affects almost 3% of the world's population and is a major worldwide health problem. Much has been learned in the past 2 decades about the treatment of these disorders. Recent developments in neuroimaging techniques have led to a better understanding of the biology of OCD and the brain circuits that may be involved in the production of symptoms. The most effective treatment approaches, based on controlled data, are behavior therapy consisting of exposure and response prevention and specific medications. Although controversial, more invasive neurosurgical and neurostimulation approaches may hold some promise for severely disabled patients. Despite impressive research efforts, a small minority of patients remain refractory to treatment. Future clinical research should focus on this refractory group.

[1]  D. Black Obsessive-Compulsive Disorders: Practical Management, 3rd ed. , 2001 .

[2]  M. Weissman,et al.  The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. , 1994, The Journal of clinical psychiatry.

[3]  Lee Baer,et al.  Obsessive-Compulsive Disorders: Practical Management , 1998 .

[4]  M. Jenike,et al.  Coexistent obsessive-compulsive disorder and schizotypal personality disorder: a poor prognostic indicator. , 1986, Archives of general psychiatry.

[5]  J H Greist,et al.  Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. , 1995, Archives of general psychiatry.

[6]  S. Freud The Standard Edition of the Complete Psychological Works of Sigmund Freud , 1953 .

[7]  M. Jenike,et al.  Stereotactic radiofrequency thermal cingulotomy for obsessive compulsive disorder. , 1961, The Journal of neuropsychiatry and clinical neurosciences.

[8]  T. Insel,et al.  Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. , 1983, Archives of general psychiatry.

[9]  Dc Washington Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[10]  E. Moniz PREFRONTAL LEUCOTOMY IN THE TREATMENT OF MENTAL DISORDERS , 1937 .

[11]  E. Foa,et al.  Differential effects of exposure and response prevention in obsessive-compulsive washers. , 1980, Journal of consulting and clinical psychology.

[12]  B. Leventhal,et al.  Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder. , 2002, Journal of child and adolescent psychopharmacology.

[13]  C. McDougle,et al.  Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. , 1995, The Journal of clinical psychiatry.

[14]  D. Black Obsessive-Compulsive Disorders: Theory and Management, 2nd ed , 1991 .

[15]  J. Leckman,et al.  The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. , 1986, The New England journal of medicine.

[16]  M. Jann,et al.  Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. , 1992, Clinical pharmacy.

[17]  M. Jenike,et al.  An open trial of buspirone in obsessive-compulsive disorder. , 1988, The American journal of psychiatry.

[18]  S. Rauch,et al.  Neurobiological models of obsessive-compulsive disorder. , 1993, Psychosomatics.

[19]  C. McDougle,et al.  A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. , 1991, Journal of clinical psychopharmacology.

[20]  M. Jenike,et al.  Obsessive-Compulsive Disorders: Theory and Management , 1986 .

[21]  M. Drake Diagnostic and Statistical Manual of Mental Disorders (3rd ed. rev.) , 1988 .

[22]  E. Foa Failure in treating obsessive-compulsives. , 1979, Behaviour research and therapy.

[23]  M. Jenike,et al.  Monoamine oxidase inhibitors in obsessive-compulsive disorder. , 1983, The Journal of clinical psychiatry.

[24]  Young Cr,et al.  Clozapine and refractory obsessive-compulsive disorder: a case report. , 1994 .

[25]  T. Insel,et al.  Obsessive—Compulsive Disorder as a 5-HT Subsystem-Related Behavioural Disorder , 1989, British Journal of Psychiatry.

[26]  C. McDougle,et al.  The role of central oxytocin in obsessive compulsive disorder and related normal behavior , 1994, Psychoneuroendocrinology.

[27]  D. Murphy,et al.  Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. , 1998, The Journal of clinical psychiatry.

[28]  A. McIntyre,et al.  A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder , 1993, European Neuropsychopharmacology.

[29]  C. Gonsalvez,et al.  Response inhibition deficits in obsessive–compulsive disorder , 2002, Psychiatry Research.

[30]  M. Jenike Augmentation Strategies for Treatment‐Resistant Obsessive‐Compulsive Disorder* , 1993, Harvard review of psychiatry.

[31]  Rapoport Jl,et al.  Obsessive-compulsive disorder: evidence for basal ganglia dysfunction. , 1988 .

[32]  S. Hyman,et al.  A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. , 1990, The American journal of psychiatry.

[33]  Harold I. Kaplan,et al.  Comprehensive textbook of psychiatry/III , 1980 .

[34]  THEODOREP. Zahn,et al.  Treatment of Patients with Obsessive Compulsive Disorder , 2006 .

[35]  M. Jenike,et al.  Standardized assessment of personality disorders in obsessive-compulsive disorder. , 1990, Archives of general psychiatry.

[36]  N. Alpert,et al.  Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. , 1994, Archives of general psychiatry.

[37]  D. Murphy,et al.  Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. , 1991, The American journal of psychiatry.

[38]  C. McDougle,et al.  Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. , 1990, The American journal of psychiatry.

[39]  D. Murphy,et al.  A Controlled Comparison of Adjuvant Lithium Carbonate or Thyroid Hormone in Clomipramine‐Treated Patients with Obsessive‐Compulsive Disorder , 1991, Journal of clinical psychopharmacology.

[40]  J. Rapoport,et al.  Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. , 1997, The American journal of psychiatry.

[41]  A. Bulbena,et al.  Clomipramine versus Phenelzine in Obsessive–Compulsive Disorder , 1992, British Journal of Psychiatry.

[42]  R. Michels,et al.  Diagnostic and Statistical Manual of Mental Disorders, 3rd ed , 1981 .

[43]  S. Sorenson,et al.  The epidemiology of obsessive-compulsive disorder in five US communities. , 1988, Archives of general psychiatry.

[44]  C. McDougle,et al.  Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. , 1994, Archives of general psychiatry.

[45]  C. McDougle,et al.  Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. , 1995, The American journal of psychiatry.

[46]  M. Jenike Neurosurgical treatment of obsessive-compulsive disorder , 1998, British Journal of Psychiatry.

[47]  M. Jenike,et al.  Obsessive-compulsive and related disorders. , 2020, Handbook of clinical neurology.

[48]  M. Jenike Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. , 1993, Psychopharmacology bulletin.

[49]  M. Jenike,et al.  Age of onset of major subtypes of obsessive—compulsive disorder , 1990 .

[50]  G. Maina,et al.  Predictors of drug treatment response in obsessive-compulsive disorder. , 1995, The Journal of clinical psychiatry.

[51]  M. Jenike,et al.  Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. , 1991, Archives of general psychiatry.

[52]  J. Mazziotta,et al.  Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. , 1988, The American journal of psychiatry.

[53]  W. Agras,et al.  Clomipramine, Clonazepam, and Clonidine Treatment of Obsessive‐Compulsive Disorder , 1992, Journal of clinical psychopharmacology.

[54]  M. Jenike,et al.  Drs. Jenike and Baer Reply , 1988 .

[55]  T. Insel,et al.  Toward a neuroanatomy of obsessive-compulsive disorder. , 1992, Archives of general psychiatry.

[56]  Laporta Ld More on obsessive-compulsive symptoms and clozapine. , 1994 .

[57]  D. C. Olivier,et al.  Prodromes of Depression and Anxiety , 1989, British Journal of Psychiatry.

[58]  C. McDougle,et al.  The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. , 1992, The Journal of clinical psychiatry.

[59]  M E Phelps,et al.  Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. , 1996, Archives of general psychiatry.

[60]  D. Murphy,et al.  Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. , 1993, The American journal of psychiatry.

[61]  I. Marks Review of behavioral psychotherapy, I: Obsessive-compulsive disorders. , 1981, The American journal of psychiatry.

[62]  J. Mazziotta,et al.  Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. , 1992, Archives of general psychiatry.